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SPECIAL REPORT
Despite the well-proven, safe and effective therapies for 
hepatitis B infection, delivery of treatment remains a signifi-
cant challenge in resource-poor settings. Geopolitical and 
economic restrictions present additional difficulties in provid-
ing care in North Korea. However, treatment of patients with 
chronic hepatitis B remains a top priority for both the North 
Korean Ministry of Public Health and international agen-
cies working in North Korean hepatitis healthcare facilities. 
Working in partnership, a path was created to institute this 
much-needed program. A consortium of United States and 
Australian humanitarian non-governmental organizations 
along with generous individual and corporate donors work-
ing in concert with local and national health authorities have 
succeeded in establishing the first hepatitis B treatment pro-
gram in North Korea. The essential elements of this program 
include renovation of existing hepatitis hospitals, access to 
antiviral medications, establishment of laboratory facilities, 
creation of medical documentation and record-keeping, 
training of local health care professionals, and quarterly visits 
by international volunteer physicians and laboratory experts. 
Management and treatment decisions are made bilaterally. 
To date, nearly 1,500 patients have been evaluated, and 
over 800 have been started on long-term antiviral therapy. It 
is envisioned that this program will eventually be managed 
and funded by the Democratic People’s Republic of Korea 
Ministry of Public Health. This program’s success demon-
strates a potential model for delivery of antiviral therapy for 
patients suffering from hepatitis B in other developing coun-
tries. (Gut Liver 2018;12:615-622)
Key Words: Hepatitis B; Antiviral therapy; Democratic Peo-
ple’s Republic of Korea; HOPE Program; Cirrhosis
INTRODUCTION
Lost among the tensions on the Korean Peninsula over the 
past years has been the continued suffering of 25 million or-
dinary North Korean citizens, many who bear untold hardship 
from malnutrition, natural disasters, and disease. Economic and 
political challenges have reduced the number of international 
aid agencies providing assistance and have limited the scale of 
their efforts. Such work not only provides much needed support 
but represents a model of ongoing cooperation and understand-
ing during difficult times. We describe how Christian Friends of 
Korea (CFK), a non-governmental organization (NGO) based in 
the United States works alongside the North Korean Ministry of 
Public Health (MoPH) to fight diseases such as chronic hepa-
titis B (CHB), treating patients and advocating for their needs. 
This partnership shows how cooperation and good-will can be 
achieved while positively impacting the health of its citizens. 
Apart from the obvious political tensions, tightened US 
and United Nations (UN) sanctions in 2017 have effectively 
stopped most humanitarian work. Special licenses from the U.S. 
Departments of Treasury and Commerce are required for the 
procurement and shipping of all goods by American NGOs. UN 
sanctions adopted in December 2017 now prohibit any metal 
(including medical supplies such as phlebotomy needles) from 
being delivered to the Democratic People’s Republic of Korea 
(DPRK), requiring NGOs to appeal to the UN Sanctions Com-
mittee for exemptions. Enhanced Chinese customs restrictions 
prohibit many critical goods required for humanitarian engage-
ment; wire transfers to longtime Chinese suppliers engaged 
in procurement activities on behalf of NGOs are now being 
blocked; and third-party vendors (banks, suppliers, shipping 
companies, etc.) scrutinize transactions or refuse to do business 
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with NGOs out of fear of violating sanctions, even when licens-
es are in place. Containers of relief supplies have been held up 
in ports for lengthy periods while custom officials work through 
the legal complexity of new sanctions, leading to delays in ship-
ping, additional costs and program setbacks. 
The obstacles faced by foreign aid agencies working in the 
DPRK, while always daunting, are now enormous. Nearly ev-
ery aspect of providing modern medical care is fraught with 
difficulty. Hospitals and care centers need renovation, clean 
water, reliable power, and medications for hepatitis have not 
been available. Laboratory facilities are outdated and many lack 
equipment and reagents. While there is no shortage of physi-
cians in the DPRK, many have restricted access to updated 
information. Visits by foreign partners must be vetted across 
multiple governmental entities, and logistics organized and co-
ordinated with local, provincial and central authorities. Ameri-
can humanitarian aid workers are now required to apply to the 
U.S. Department of State for an exemption from the travel ban 
for each visit that they make. MoPH personnel accompany for-
eign visitors, yet they, too, are understaffed, limiting the person-
nel and visits that can be facilitated each year. Those from other 
countries are often reluctant to volunteer under the current un-
certain security environment. Patients themselves are uncertain 
as to what to expect and can be wary of foreign (particularly 
American) health care providers, at least at the onset. 
Outside of UN and World Health Organization (WHO)-
supported work which is currently underfunded, most external 
medical aid programs in North Korea are undertaken by a 
handful of NGOs (with limited staffing and budgets) that have 
pursued principled engagement, some for two decades or more. 
More than anywhere else in the world, trust and partnership be-
tween NGOs, local authorities and the MoPH remain critical.
For many years the MoPH had identified hepatitis B as a 
priority disease in the DPRK and made requests to NGOs to 
address shortfalls in all aspects of hepatitis B care. Prevalence 
rates are likely to reflect those of similar countries of compa-
rable background and are likely to be high.1 Vaccination gaps 
in children had been addressed as part of an Expanded Program 
of Immunization in 2003 for infants and children and a catch-
up vaccination program took place in 2009.2 A further 7 million 
children were vaccinated between 2010 and 2012. However, 
most adults and at-risk individuals such as health care workers 
and close contacts of infected individuals remain untested and 
unvaccinated. Furthermore, antiviral treatment programs to care 
for those with CHB were essentially non-existent. Requests for 
antiviral medications and laboratory capacity came repeatedly 
from local doctors during visits by volunteers from CFK who 
were checking on clean water projects or deliveries of blankets, 
greenhouses, and tractors at health care facilities. While preven-
tion remains the key to controlling this epidemic, the daunting 
task of treating those with CHB was a challenge that could not 
be ignored.
THE HOPE PROGRAM
Antiviral therapy for hepatitis B has been available for over 
two decades in settings where its high cost is affordable. How-
ever, even in wealthy countries, only a minority of those who 
need therapy are actually receiving it. Limited amounts of these 
medications are now reaching those who live in less developed 
nations where the disease burden is the greatest. To date, the 
challenges in delivering antiviral therapy for hepatitis B have 
been considered too onerous to overcome and hence, large-
scale treatment programs have been left off the table. In con-
trast, highly effective human immunodeficiency virus therapy is 
widely available in the most resource-challenged settings which 
raises the question as to why hepatitis B treatment (which often 
includes the same medications) should not be equally accessible.
The WHO recognized this incongruence and in 2015 pub-
lished global guidelines for the prevention, care and treatment 
of CHB, with resource-limited regions in mind (see a summary 
in Table 1).3 These guidelines simplified the algorithm for treat-
ment while taking into account budgetary constraints and 
limited availability of laboratory investigations. Point of care 
(POC) kits for key hepatitis tests, some with sensitivities and 
specificities approaching traditional laboratory-based tests are 
affordable and widely available. Treatment decisions with the 
new guidelines can be made in the absence of viral load testing. 
Thereby, a new pathway for the treatment of hepatitis B opened 
in the DPRK and other regions of the world with a high preva-
lence of CHB but limited resources. 
In order to implement such a project in the DPRK, essential 
requirements included access to patients, medical personnel, 
hospitals, medications, ultrasound, and laboratory services. An 
alliance of NGOs and generous donors was formed to provide 
CFK with additional expertise and resources (Table 2). CFK has 
been working in the DPRK since 1995, providing aid after floods 
and other natural disasters, delivering food and medicines at 
health-care facilities and rest homes, and engaging in capacity-
building projects in technical areas such as agriculture, clean 
water, renewable energy, infrastructure, tuberculosis diagnostics 
and education. It has established important contacts within the 
MoPH and with local and regional government officials. An 
Australian NGO, Hepatitis B Free (HBF), was formed to facili-
tate prevention of and delivery of care for hepatitis B in areas 
with limited access to healthcare. Global Care Partners (GCP) is 
an American NGO that focuses on the improvement of clinical 
laboratory diagnostic services in resource-challenged countries 
through on-site education and training, consultation, laboratory 
assessment and design, and procurement of appropriate labora-
tory equipment. All three organizations came together to work 
with the MoPH to initiate a pilot program to provide hepatitis B 
care to patients in the DPRK.
A memorandum of understanding (MOU) between the pro-
gram partners and the MoPH was negotiated, and a program 
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protocol document called HOPE (Hepatitis B Overview and 
Program to Treat) was created. The MOU delineated the respon-
sibilities of the MoPH and NGOs and the objectives of the pro-
gram. The primary aim was to: “…provide antiviral therapy for 
treatment of eligible patients in the DPRK, to improve patient 
outcomes and reduce morbidity and mortality from hepatitis 
B related illnesses through a program of testing, treatment and 
follow-up.” Secondary objectives included the development 
of preventative strategies to reduce new infections, to increase 
screening and case identification with linkage to treatment, and 
to provide education and training. The duration of the program 
was envisioned to be 10 years with a goal of treating 5,000 pa-
tients with CHB. If the number of patients on treatment exceeds 
this number, appeals for new donations will be made. At the 
end of this period, the objective is that the program will be self-
sustaining with local physicians and the MoPH fully capable of 
carrying on the program without outside assistance.
INFRASTRUCTURE DEVELOPMENT
The two initial sites selected for the pilot program were the 
Pyongyang #2 (Hepatitis) Prevention Hospital and Kaesong 
#2 (Hepatitis) Prevention Hospital. Pyongyang #2 Prevention 
Hospital, located in the capital, is the referral center for patients 
with hepatitis in Pyongyang City. The hospital has a labora-
tory, pharmacy and Korean traditional medicine department 
and supports both inpatient and outpatient care. Therapeutic 
and diagnostic endoscopic procedures (fewer than 20 per year) 
are offered when equipment is working, and consumables such 
as variceal band ligators are available through donations. The 
hospital is connected to grid power, but due to inconsistent 
power supply, a solar/battery array with a backup generator 
often serves as the main power source. The second site is Kae-
Table 1. Summary of WHO Recommendations for Persons with CHB When Viral Load Testing Is Not Available3
Evaluation for cirrhosis
APRI >2 or Fibroscan score consistent with cirrhosis, decompensated liver disease 
Who to treat
All patients with cirrhosis
Patients over 30 years with persistently abnormal ALT
Choice of treatment
First line treatment with entecavir or tenofovir
Entecavir for children 2–11 years
In patients with suspected antiviral resistance to other drugs, switch to tenofovir
When to stop treatment
Lifelong treatment in patients with cirrhosis
Without cirrhosis, after at least 1 year of treatment with loss of HBsAg positivity and persistently normal ALT
Restart treatment if signs of reactivation (HBsAg becomes positive, ALT levels increase)
Monitoring
At least annually: ALT, AST, creatinine, HBsAg, HBeAg, platelets, APRI, Fibroscan, adherence
More frequently: during first year of treatment, advanced disease, fluctuating ALT if not on treatment, after discontinuation of therapy
Abdominal ultrasound and alpha-fetoprotein (if available) every 6 months if cirrhotic or family history of hepatocellular carcinoma
WHO, World Health Organization; CHB, chronic hepatitis B; APRI, aspartate aminotransferase (AST) to platelet ratio index; ALT, alanine amino-
transferase; HBsAg, hepatitis B surface antigen; HBeAg, hepatitis B e antigen. 
Table 2. Contributions of NGO in HOPE
Christian Friends of Korea (CFK), Black Mountain, NC, USA
Overall coordination of program with MoPH and US authorities
Infrastructure development (water, electricity, building construc-
tion)
Import licenses, transport and storage of supplies and medications
Maintenance of patient database and medical records
Hepatitis B Free (HBF), Sydney, Australia
Overall responsibility for treatment of hepatitis patients
Acquisition of antivirals
Patient medical records
Recruitment of volunteer physicians
Training of local physicians
Global Care Partners (GCP), Berrien Springs, MI, USA
Overall responsibility for clinical diagnostic testing of patients’ 
specimens
Design of laboratory facilities 
Acquisition of laboratory supplies and analyzers
Training of local laboratory personnel
NGO, non-governmental organization; HOPE, Hepatitis B Overview 
and Program to Treat; MoPH, Hepatitis B Overview and Program to 
Treat.
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song #2 (Hepatitis) Prevention Hospital, situated in the outskirts 
of Kaesong City, 174 km south of Pyongyang. The hospital is 
comprised of several one-story buildings with both inpatient 
and outpatient care facilities. It serves as the referral center for 
patients with hepatitis in Kaesong City. There was no centrally 
distributed power or water available at this facility when the 
project first began. A third site in the coastal city of Haeju in 
southwest North Korea is under renovation, and the first cohort 
of patients was recently screened for treatment. A fourth site 
has also been identified and funding sources are being pursued.
The first and most difficult challenge was to create laboratory 
infrastructure, but significant work had already begun. Since 
2008, GCP has been collaborating with CFK in the DPRK as-
sisting with planning, renovating, and equipping the National 
Tuberculosis Reference Laboratory (NRL) in Pyongyang as tu-
berculosis remains the other major public health burden in the 
DPRK.4 GCP helped create a clinical laboratory concurrent with 
the development of the tuberculosis-specific diagnostics at the 
NRL. The clinical lab provided hematology, chemistry, immu-
nology, and body fluid diagnostics, and GCP supported bi-an-
nual training for the staff to develop their skills. The laboratory 
professionals who trained at Pyongyang now serve as instruc-
tors at the newer sites. Important additions to the laboratory 
capability which were facilitated by GCP included the provision 
of hematology and biochemistry analyzers.5
CFK has substantial technical expertise in the construction 
and renovation of buildings, including the NRL, as well as the 
provision of clean water and power. Using this experience base, 
two solar-powered, modern clinical labs with newly drilled 
wells at the pilot sites in Pyongyang and Kaesong were built 
and equipped, supported by private fundraising and volunteers 
from CFK, HBF, and GCP, who worked closely with local hospi-
tal staff. The laboratory in Pyongyang was recently designated 
as the National Hepatitis Reference Laboratory. 
TREATMENT
Review of priority patients for therapy started in late fall, 
2015, and treatment protocols were developed based on WHO 
guidelines, with some adjustment made for the local context. 
Each aspect of this program was negotiated in detail with the 
local partners. Negotiations at times were delicate, and patience 
was constantly tested on both sides. Screening and confirmation 
that patients were hepatitis B surface antigen positive was the 
first step. Patients over the age of 18 were considered eligible. 
Those between 3 and 17 years old were enrolled after discussion 
with a pediatrician and the patient’s guardian. Eligibility criteria 
for treatment were consistent with WHO and recognized inter-
national hepatology guidelines. Treatment exclusion criteria 
include known sensitivity to treatment drugs, life expectancy 
of less than 6 months from any cause, and inability to comply 
with the treatment protocol (Table 3). All patients with CHB and 
cirrhosis are deemed highest priority for therapy. In those with-
out cirrhosis, persistent elevation in alanine aminotransferase 
(ALT) and risk of progression of liver disease are considerations 
to initiate treatment (Fig. 1). All patients are asked to sign an 
agreement to comply with each program requirement including 
periodic diagnostic testing, attendance for follow-up visits and 
compliance with medications. Country-specific patient educa-
tional resources were prepared in Korean and approved by local 
authorities for use. 
The program requires that both a qualified international 
physician and a locally trained physician assess each potential 
patient prior to initiating treatment. This evaluation includes 
clinical history, physical examination and careful assessment of 
laboratory and radiologic investigations. Clinical laboratory as-
sessment includes confirmation of hepatitis B status using POC 
tests for hepatitis B surface antigen (HBsAg), surface antibody 
(HBsAb), e antigen (HBeAg), and hepatitis C antibody (HCV Ab). 
Both SD Bioline (SD Bioline Seoul, South Korea; Alere Diagnos-
tics, Waltham, MA USA) and ABON (ABON Biopharm, Hang-
zhou, China) POC tests were selected to ensure access to more 
than one supply source (see Table 4). Biochemical parameters 
include a complete blood count (CBC) as well as analyzer mea-
surements of aspartate aminotransferase (AST), ALT, and creati-
nine (Cr). With these values a calculation of the AST to platelet 
ratio index can be made to determine eligibility for treatment, as 
indicated in the WHO guidelines. Negotiations are currently un-
derway to add other tests such as quantitative hepatitis B DNA 
viral load, but ongoing costs in supplying the lab currently limit 
the addition of new capabilities and staff training. Selection of 
the analyzers was based on equipment reliability and availabil-
ity of inexpensive, high-quality consumables. An ultrasound is 
performed on each patient looking for signs of cirrhosis, ascites, 
splenomegaly, and portal hypertension as well as surveillance 
for liver masses, both benign and malignant. All ultrasound 
equipment was donated. Additionally, a FibroscanTM (Echosense, 
Paris, France) machine was provided by a generous donor and 
has been invaluable in staging liver disease and guiding treat-
ment decisions. Based on history, physical examination, lab 
Table 3. Inclusion and Exclusion Criteria
Inclusion criteria
Hepatitis B surface antigen positive
Age 18 or above (ages 3–17 if approved by pediatrician and guard-
ian)
Exclusion criteria
Inability to comply with program requirements (non-compliance 
with medications and clinic visits, continued alcohol abuse, re-
fusal of lab testing)
Life expectancy <6 months
Known allergy to or intolerance of drugs
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results, ultrasound and FibroscanTM patients are prioritized for 
treatment per WHO guidelines (Fig. 1). A goal of this program 
has been to maintain cost efficiency without compromise to pa-
tient care. 
Patient access to life-long antiviral therapy in a country 
where programmatic transition to local health authorities is 
uncertain was a significant challenge. The first identified prior-
ity was to find a way to procure medicines for the DPRK and to 
establish a pathway for medicines to be imported into a country 
that was subject to sanctions. After many months of negotia-
tions including extensive legal counsel to ensure compliance 
with international sanctions, a donor commitment for the first 
cohort of patients for therapy was confirmed. This continues to 
be a work in progress with the need for constant reevaluation 
as program requirements and limitations on imports change. 
The most effective antivirals for CHB, tenofovir and entecavir, 
were ordered and arrived in the summer of 2016, just in time to 
start a small cohort of the sickest patients on treatment. To date 
nearly 1,500 patients have been screened by teams of interna-
tional volunteer physicians, and over 800 have started antiviral 
therapy (see Table 5 for baseline characteristics). External team 
visits occur four times per year and patients are seen at least 
twice annually. Each visit includes interval history, physical 
examination, lab testing (ALT, Cr, platelets) and ultrasound for 
liver cancer screening. Annual HBsAg testing is done, and Fi-
broscan is performed on a bi-annual basis to document disease 
progression or regression. Patients are counseled, and compli-
ance is reinforced. 
Clinical reviews are accomplished on each patient with local 
and international doctors working side by side; treatment deci-
sions are made jointly, often after prolonged discussions. Skills 
transfer occurs bilaterally across all elements of the project. In 
time this program will belong to the local healthcare workers, 
and it is essential to empower them with all the tools needed 
to take full ownership. Nearly all patients have been seen in 
follow-up, many with a new lightness in their hearts and with 
hope for a brighter future. Approximately 30 of the sickest 
Initiate treatment and monitor
Tenofovir or entecavir
Entecavir for ages 2 11 yr and GFR <40 mL/min
Consider treatment if:
Age >30 yr and ALT persistently abnormal, or
Significant symptomatology attributable to CHB (clinical judgment)
Otherwise,






Fibroscan score >12 kPa
Fig. 1. Simplified guidelines for selection of patients to undergo treatment.
HBsAg, hepatitis B surface antigen; APRI, aspartate aminotransferase to platelet ratio index; GRF, glomerular filtration rate; ALT, alanine amino-
transferase; CHB, chronic hepatitis B. *Clinical signs and symptoms of decompensated cirrhosis include ascites, variceal bleeding, hepatic encepha-
lopathy, jaundice, extrahepatic symptoms. Adapted from World Health Organization (WHO) treatment guidelines, 2015.3
Table 4. Point of Care Hepatitis Test Characteristics
SD Bioline HBsAg Rapid Test





ABON Hepatitis B Combo Test (HBsAg, HBsAb, HBeAg, HBeAb, 
HBcAb)




SD Bioline HCV IgG Rapid Test





HBsAg, hepatitis B surface antigen; HBsAb, hepatitis B surface anti-
body; HBeAg, hepatitis B e antigen; HBeAb, hepatitis B e antibody; 
HBcAb, hepatitis B core antibody. 
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patients have died despite starting therapy. Although records 
are not available which show the exact cause of death, it is pre-
sumed that they died from complications of end-stage liver dis-
ease. Others remain critically ill including a young mother who 
decompensated during child birth and now hopes that treatment 
will give her a chance to see her daughter grow to adulthood, 
and young men with new diagnoses of liver cancer which re-
mains universally fatal in the DPRK. 
DRUG DISPENSING AND ACCOUNTABILITY
For the integrity of the program, a precise accounting of all 
medicines donated is absolutely essential. There are four stages 
of accountability of antiviral medications supplies including: 
receipt in country, onward shipping to treatment centers, treat-
ment center receipt, and patient dispensing and accountability. 
On arrival in country at the central depot, each shipment of 
antiviral drugs must be recorded on the drug shipment receipt 
log as received and a physical count taken. Onward shipments 
to treatment centers from the central depot are recorded on 
shipping logs located at the clinics, and another physical count 
is taken. Each treatment center must have its own individual 
folder containing its shipment receipt logs which are kept under 
separate physical control from the pharmacist who manages 
the individual patient dispensing and accountability logs. Each 
treatment center has its own drug shipment receipt log to docu-
ment when antiviral medications arrive on site. 
PROGRAM DOCUMENTATION 
An electronic medical record system utilizing bar code scan-
ning has been developed, despite the lack of internet connectiv-
ity or grid power. It became apparent after the first clinic visits 
that using paper records would soon become untenable as the 
program expanded. Lab results had to be manually entered into 
the Microsoft Access data base that was developed for the HOPE 
program. Each document generated during the clinic visit would 
need to be scanned at the end of the work day, and this became 
overly time-intensive for the team, even with only 100 patients 
per clinic day. After much discussion, a decision was made to 
develop an ad hoc system utilizing bar codes and fillable clinic 
forms that could be saved on laptop computers. 
At the heart of the electronic system is a Microsoft Access 
data base where the master files reside. Upon entry into the pro-
gram a patient is photographed with their unique patient num-
ber that is imprinted onto an identification card with a comput-
er-generated bar code. Bar code labels are printed and affixed to 
the sample collection tubes when the patient has blood drawn. 
These tubes are sent to the lab and the bar code scanner on the 
lab analyzer reads the patient’s identification number and au-
tomatically stores the lab results in its internal memory. The lab 
values can later be downloaded from the analyzer as an Access 
file and uploaded into the main data base. 
Meanwhile, each physician brings a laptop to clinic and at-
taches a barcode scanner to the computer. Fillable forms using 
Microsoft Word with drop-down menus and click boxes have 
been developed for the initial visit and follow-up appointments. 
These documents are password protected. When a patient ar-
rives at the examination station, his/her identification is con-
firmed, the identification card is scanned and the corresponding 
demographic information and lab values automatically populate 
the encounter forms. The provider also has access to all previous 
clinic visits and lab values through the Access data base. The 
visit can be efficiently documented with a series of clicks and a 
typed impression at the end of the form. At the end of the clinic 
day, each provider uploads the saved files onto a USB drive, the 
content of which is placed in the master data base, eliminating 
the need to scan or copy paper forms. This system has worked 
Table 5. Characteristics at Baseline of Patients on Treatment
Clinic Pyongyang Kaesong
Total patients on treatment 604 249
Age, yr* 43.82 (13–71) 44.81 (19–65)
Sex, male/female 426/178 170/79
Fibroscan score, kPa 16.1 (3.5–75) 17.8 (3.5–75)
APRI 2.32 (0.10–56.0) 2.01 (0.27–28.88)
Platelets, ×109/L 118 (12–358) 124 (19–648)
Cirrhotics, % of total by Fibroscan† 63.4 69.2
Cirrhotics, % of total by APRI‡ 57.0 50.2
ALT, IU/L 59.8 (5.0–955.0) 53.9 (12.0–988.4)
AST, IU/L 64.0 (5.0–1,373.0) 60.6 (18.0–493.5)
Patients on antivirals, tenofovir/entecavir 470/134 197/52
Data are presented as number or median (range).
APRI, aspartate aminotransferase (AST) to platelet ratio index; ALT, alanine aminotransferase.
*Mean (range); †Fibroscan score ≥12.0 kPa; ‡APRI ≥2.0.
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well without the need for a local area network or internet and 
has allowed the clinic to expand without being inundated by 
paper documentation. Future challenges will be to train local 
providers to use this system, to provide hardware, such as lap-
tops, for them to use during clinic visits, and to maintain qual-
ity control. 
TRAINING, ADVOCACY, AND EDUCATION
A critical component of the program is training local physi-
cians, nurses, lab technicians, and data managers in order to 
insure sustainability. Lectures, demonstrations, and hands-on 
training are an integral part of laboratory training. Each time 
one of the clinic sites is visited, the international physicians 
provide in-depth lectures on the prevention and treatment of 
hepatitis and associated complications to local staff. This train-
ing has been very well-received with increased bilateral un-
derstanding of the requirements and barriers to improved care. 
Training of local staff continues to remain a challenge as travel 
within the DPRK by health professionals is discouraged, and 
time and cost constraints on international instructors often limit 
the number of sites that can be visited. Even when the team is 
in country, access to the health care workers for training is not 
always possible given the competing demands for their time. 
Advocacy is critical to address current gaps and opportuni-
ties in hepatitis services, to raise awareness about the burden 
of hepatitis in DPRK, and to enable long-term sustainability for 
the program, including funding and policy. Promotion of pre-
ventative strategies is essential including vaccination of high-
risk groups, interruption of mother to child transmission, and 
decreasing healthcare-transmitted infections (including injection 
safety, universal precautions, and blood bank safety). Decision-
makers must be encouraged to enact policies that enable im-
provement of hepatitis services. In addition to the MoPH, regu-
lar meetings have been held with in-country stakeholders such 
as WHO, United Nations Children’s Fund (UNICEF), and other 
NGOs to advocate for additional funding and awareness. 
Education of the public, including affected patients and their 
families, is also a primary objective. Upon entrance into the 
program each patient receives a handbook that illustrates in 
easy to understand language some of the key principles of the 
disease, its prognosis, possible side effects of medications, car-
ing for oneself, and preventing transmission. Information sheets 
are given to patients that describe the HOPE program and give 
more detail about the natural history of CHB. During each visit, 
patients are given ample opportunity to ask questions and to 
inquire about the results of their tests. Patients are encouraged 
to refer family members or friends from their neighborhoods or 
villages to the clinic for testing if their acquaintances have simi-
lar signs and symptoms. Many have done so already.
FUTURE DIRECTIONS
In working together to tackle a disease of staggering propor-
tions in the DPRK, we have found ways to effectively navigate 
difficult waters, communicate and cooperate despite severe 
sanctions. Our experience has been invaluable in creating a 
model for treatment of CHB in other resource-poor regions with 
high burdens of disease. Already, our experience is being used 
to start similar programs in western Pacific islands such as Kiri-
bati, some of which have the highest rates of CHB in the world. 
Ongoing advocacy to further reduce prices (in all elements of 
hepatitis care) and to provide funding and availability for hepa-
titis B treatment and prevention should be emphasized to insure 
equitable access to care throughout the world. 
In the DPRK we have only begun to scratch the surface of 
the nation’s hepatitis needs, and it is unlikely that our small 
team can make a significant dent in the overall burden of CHB. 
However, for the patients and their families we have met, it is 
an important start and a source of real hope. Despite significant 
barriers such as travel restrictions on volunteers and a vulnera-
ble supply chain, we plan to move forward as long as it remains 
possible for us to enter the DPRK safely.
A third clinic site has been approved and funding obtained to 
establish a program at the South Hwanghae #2 Prevention Hos-
pital in Haeju, located in the southwestern region of the DPRK. 
Construction and renovation have been interrupted by enhanced 
sanctions but are expected to resume soon. The first patients 
were seen in Haeju during the first half of 2018, supported by 
the laboratory in Pyongyang. Expansion of lab capabilities to 
include viral load testing is envisioned to improve diagnostics 
for hepatitis B and to enable treatment of hepatitis C. Viral load 
testing would also facilitate treatment of pregnant women who 
are infected with CHB in accordance with recognized protocols; 
this would be an important milestone in the prevention of verti-
cal transmission of hepatitis B. As we build capacity, each step 
forward becomes more complex for both visitors and local part-
ners. 
On a personal level we worry about the fate of our patients 
who have benefited from treatment and for those we have yet to 
meet. In a broader sense, we have witnessed the extraordinary 
value of a cooperative health program in cultivating good-will 
and understanding while positively impacting a serious health 
problem. We have felt the gratitude and genuine comradery 
that has developed between all of the partners and over 1,500 
patients. We hear their appeals at the end of each visit for us to 
return soon. 
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